Ubs Oconnor LLC Editas Medicine, Inc. Transaction History

Ubs Oconnor LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $88,556 - $139,448	-12,597 Reduced 25.19%	37,403 $277,000
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $202,306 - $359,619	-32,369 Reduced 39.3%	50,000 $506,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $523,866 - $944,772	82,369 New	82,369 $678 Million
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $450,271 - $738,496	64,050 New	64,050 $464,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.